Details of the Drug

General Information of Drug (ID: DM9HPW3)

Drug Name
Exemestane
Synonyms
Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione
Indication
Disease Entry ICD 11 Status REF
Hormonally-responsive breast cancer 2C60-2C65 Approved [1]
Male breast carcinoma N.A. Investigative [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 296.4
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The absorption of drug is 42% []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 24 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.34947 micromolar/kg/day [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cardiovascular disorder Not Available AK1 OT614AR3 [6]
Chemical Identifiers
Formula
C20H24O2
IUPAC Name
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
Canonical SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C
InChI
InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
InChIKey
BFYIZQONLCFLEV-DAELLWKTSA-N
Cross-matching ID
PubChem CID
60198
ChEBI ID
CHEBI:4953
CAS Number
107868-30-4
DrugBank ID
DB00990
TTD ID
D0D2VS
INTEDE ID
DR0675
ACDINA ID
D00261
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2) OTGVC9MY PLCG2_HUMAN Gene/Protein Processing [9]
Adenylate kinase isoenzyme 1 (AK1) OT614AR3 KAD1_HUMAN Drug Response [6]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Gene/Protein Processing [10]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Protein Interaction/Cellular Processes [11]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [12]
ATP-binding cassette sub-family G member 4 (ABCG4) OT2XJIOG ABCG4_HUMAN Gene/Protein Processing [9]
CD83 antigen (CD83) OT1V4WQF CD83_HUMAN Gene/Protein Processing [9]
Disabled homolog 2 (DAB2) OTRMQTMZ DAB2_HUMAN Gene/Protein Processing [9]
Dynein axonemal assembly factor 9 (DNAAF9) OTTKWWQU DAAF9_HUMAN Gene/Protein Processing [9]
E3 ubiquitin-protein ligase RNF123 (RNF123) OTL59S8J RN123_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Exemestane (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Exemestane caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Moderate Increased metabolism of Exemestane caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [13]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Exemestane caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [13]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Exemestane caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [14]
Cenobamate DM8KLU9 Moderate Increased metabolism of Exemestane caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Exemestane caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Rufinamide DMWE60C Moderate Increased metabolism of Exemestane caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Phenobarbital DMXZOCG Moderate Increased metabolism of Exemestane caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Exemestane caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Tazemetostat DMWP1BH Moderate Increased metabolism of Exemestane caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [13]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Exemestane caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [13]
Rifampin DMA8J1G Moderate Increased metabolism of Exemestane caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [14]
Rifapentine DMCHV4I Moderate Increased metabolism of Exemestane caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [13]
Etravirine DMGV8QU Moderate Increased metabolism of Exemestane caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Amobarbital DM0GQ8N Moderate Increased metabolism of Exemestane caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Brigatinib DM7W94S Moderate Increased metabolism of Exemestane caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [16]
PF-06463922 DMKM7EW Moderate Increased metabolism of Exemestane caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [13]
Vemurafenib DM62UG5 Moderate Increased metabolism of Exemestane caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [13]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Exemestane caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [13]
Exjade DMHPRWG Moderate Decreased metabolism of Exemestane caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [17]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Exemestane and Thalidomide. Multiple myeloma [2A83] [18]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Exemestane and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [19]
Abametapir DM2RX0I Moderate Decreased metabolism of Exemestane caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [20]
Lefamulin DME6G97 Moderate Decreased metabolism of Exemestane caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [21]
Enzalutamide DMGL19D Moderate Increased metabolism of Exemestane caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [13]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Exemestane and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [22]
Dexamethasone DMMWZET Moderate Increased metabolism of Exemestane caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [13]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Exemestane caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [15]
Armodafinil DMGB035 Moderate Increased metabolism of Exemestane caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Exemestane caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [23]
Elagolix DMB2C0E Moderate Increased metabolism of Exemestane caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [13]
⏷ Show the Full List of 31 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Butylated hydroxytoluene E00336 31404 Antioxidant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Crospovidone E00626 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium carbonate E00205 11029 Adsorbent; Diluent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Exemestane 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7073).
2 Exemestane FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
8 In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane. Pharmacol Res Perspect. 2017 Apr 27;5(3):e00314.
9 Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2007 Apr;40(4):876-87. doi: 10.1016/j.bone.2006.11.029. Epub 2006 Dec 28.
10 Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. Breast Cancer Res Treat. 2009 Aug;116(3):461-70. doi: 10.1007/s10549-008-0151-x. Epub 2008 Aug 3.
11 Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
12 Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
13 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
14 Product Information. Aromasin (exemestane) Pharmacia &amp Upjohn, Kalamazoo, MI.
15 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
17 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
18 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
19 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
20 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
21 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
22 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
23 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.